IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio –
– Public equity offering and concurrent private placement with gross proceeds of
“We continued to make good progress in the development of our IgM platform in the second quarter, as reflected in our announcement of encouraging data from the clinical trials of IGM-8444, now known as aplitabart, and in the clearance by the FDA of two Investigational New Drug applications to begin clinical trials of imvotamab, our IgM-based CD20 x CD3 bispecific antibody T cell engager, in severe systemic lupus erythematosus and severe rheumatoid arthritis,” said
Aplitabart (IGM-8444) (DR5 agonist)
- Clinical data with 3 mg/kg of aplitabart plus FOLFIRI from a non-randomized Phase 1 clinical trial. In
June 2023, the Company reported Phase 1 data from a cohort of patients treated with aplitabart, the Company’s IgM agonist antibody targeting death receptor 5 (DR5), in combination with FOLFIRI through a data cut-off date of April 12, 2023.
51 CRCpatients treated with the combination regimens, no drug related clinically significant hepatotoxicity was observed, with only grade 1 and grade 2 transient liver enzyme elevations noted as of the data cut-off date.
- In these predominantly third-line metastatic colorectal cancer patients, the combination of aplitabart dosed at 3 mg/kg and FOLFIRI showed promising activity in terms of progression-free survival.
- Multiple confirmed partial responses were observed among the patients treated with 3 mg/kg of aplitabart and FOLFIRI, including some patients who had previously progressed on FOLFIRI treatment.
- Clinical development of aplitabart advances. The Company continues to advance the clinical development of aplitabart.
- Dosing ongoing in the randomized colorectal cancer clinical trial. The Company is currently enrolling patients in an open-label randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in second-line metastatic colorectal cancer. This randomized trial will assess the additional benefit of 3 mg/kg of aplitabart with a primary endpoint of progression-free survival (PFS) and secondary endpoints of overall response rate and overall survival as compared to the current standard of care treatment arm of FOLFIRI and bevacizumab. The Company’s goal is to have enrolled approximately 110 patients in the trial by the end of the first quarter of 2024 and to have median PFS data from these patients by the end of 2024.
- Dosing at 10 mg/kg ongoing in the single arm colorectal cancer clinical trial. The Company has also begun dosing additional colorectal cancer patients at 10 mg/kg of aplitabart in its single arm FOLFIRI combination clinical trial.
- Dosing ongoing in the venetoclax combination. The Company is currently treating patients with acute myeloid leukemia in its aplitabart plus venetoclax and azacytidine Phase 1 combination cohort.
- Dosing ongoing in birinapant combination. The Company is also currently treating patients in its aplitabart plus birinapant Phase 1 combination cohort.
Imvotamab (CD20 x CD3)
- FDA clearance to begin autoimmune clinical trials. In the second quarter, the Company received clearance of two Investigational New Drug (IND) applications with the
U.S. Food and Drug Administration(FDA) for imvotamab, an IgM-based CD20 x CD3 bispecific antibody T cell engager, which will enable the initiation of two Phase 1b clinical trials, one in severe systemic lupus erythematosus (SLE) and one in severe rheumatoid arthritis (RA), during third quarter 2023.
IGM-7354 (IL-15 x PD-L1)
- Phase 1 trial continues. The Company continues to enroll patients in a Phase 1 clinical trial exploring the safety, efficacy and biomarker activity of IGM-7354, an IgM-targeted immunostimulatory IL-15 cytokine, in the treatment of patients with solid tumors.
IGM-2644 (CD38 x CD3)
- Phase 1 trial initiated. The Company has initiated a clinical trial exploring the safety and efficacy of IGM-2644, a CD38 x CD3 IgM T cell engaging antibody, in patients with recurrent or refractory multiple myeloma.
- Completed underwritten public offering of common stock and concurrent private placement. As previously announced, the Company recently closed a public offering of its voting and non-voting common stock and concurrent private placement of non-voting common stock, with total gross proceeds of
$120.0 millionand net proceeds of $113.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, of which $68.5 millionhad been received by the Company as of June 30, 2023and $45.0 millionwas received on July 3, 2023.
Second Quarter 2023 Financial Results
- Cash and Investments: Cash and investments as of June 30, 2023 were $386.9 million (which amount does not include an additional
$45.0 millionfrom the public equity offering received on July 3, 2023), compared to $427.2 millionas of December 31, 2022.
- Collaboration Revenue: For the second quarter of 2023, collaboration revenues were
$0.4 million, compared to $0.4 millionfor the same period in 2022.
- Research and Development (R&D) Expenses: For the second quarter of 2023, R&D expenses were
$55.7 million, compared to $47.2 millionfor the same period in 2022.
- General and Administrative (G&A) Expenses: For the second quarter of 2023, G&A expenses were
$13.0 million, compared to $12.4 millionfor the same period in 2022.
- Net Loss: For the second quarter of 2023, net loss was
$64.4 million, or a loss of $1.43per share, compared to a net loss of $58.6 million, or a loss of $1.33per share, for the same period in 2022.
2023 Financial Guidance
The Company expects full year 2023 GAAP operating expenses of
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Such forward-looking statements are not based on historical fact and include, but are not limited to: the potential of, and expectations regarding, IGM’s technology platform and its IgM antibodies and product candidates, including aplitabart and imvotamab; IGM’s plans and expectations regarding its clinical development efforts and activities; statements regarding the clinical development of aplitabart, imvotamab, IGM-7354 and IGM-2644, including the timing of initiation of clinical trials, patient enrollment and availability of clinical data; IGM’s expectations regarding its financial position and guidance, including collaboration revenue, operating expenses, stock-based compensation expense, ending 2023 cash and investments and projected cash runway; and statements by IGM’s Chief Executive Officer. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: IGM’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM’s ability to demonstrate the safety and efficacy of its product candidates; IGM’s ability to successfully and timely advance its product candidates through clinical trials; IGM’s ability to enroll patients in its clinical trials; the potential for the results of clinical trials to differ from preclinical, preliminary, initial or expected results; the risk of significant adverse events, toxicities or other undesirable side effects; IGM’s ability to successfully manufacture and supply its product candidates for clinical trials; the potential impact of continuing or worsening supply chain constraints; the risk that all necessary regulatory approvals cannot be obtained; the potential market for IGM’s product candidates, and the progress and success of alternative therapeutics currently available or in development; IGM’s ability to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM is targeting; IGM’s ability to obtain, maintain and protect its intellectual property rights; developments relating to IGM’s competitors and its industry, including competing product candidates and therapies; any potential delays or disruptions resulting from catastrophic events, including epidemics or other outbreaks of infectious disease; general economic and market conditions, including inflation; and other risks and uncertainties, including those more fully described in IGM’s filings with the
|Selected Statement of Operations Data
|(in thousands, except share and per share data)
|Three Months Ended||Six Months Ended|
|Research and development (1)||55,673||47,218||106,567||86,093|
|General and administrative (1)||12,983||12,372||25,985||25,453|
|Total operating expenses||68,656||59,590||132,552||111,546|
|Loss from operations||(68,208||)||(59,224||)||(131,582||)||(111,180||)|
|Other income (expense):|
|Total other income (expense)||3,894||629||8,046||691|
|Loss before income tax expense||(64,314||)||(58,595||)||(123,536||)||(110,489||)|
|Income tax expense||(109||)||—||(196||)||—|
|Net loss per share, basic and diluted||$||(1.43||)||$||(1.33||)||$||(2.76||)||$||(2.84||)|
|Weighted-average common shares outstanding, basic and diluted||45,122,900||43,919,092||44,796,644||38,906,839|
|(1) Amounts include stock-based compensation expense as follows:|
|Research and development||$||8,248||$||6,335||$||14,687||$||12,942|
|General and administrative||6,061||4,951||10,669||9,843|
|Total stock-based compensation expense||$||14,309||$||11,286||$||25,356||$||22,785|
|Selected Balance Sheet Data
|Cash and investments||$||386,869||$||427,162|
|Total stockholders' equity||258,607||287,263|
Source: IGM Biosciences, Inc.